Ituran Location and Control (NASDAQ: ITRN) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap industrial products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.
This is a breakdown of current ratings and price targets for Ituran Location and Control and Interpace Diagnostics Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ituran Location and Control||0||0||1||0||3.00|
|Interpace Diagnostics Group||0||0||1||0||3.00|
Ituran Location and Control presently has a consensus price target of $31.00, suggesting a potential downside of 11.81%. Interpace Diagnostics Group has a consensus price target of $5.00, suggesting a potential upside of 290.63%. Given Interpace Diagnostics Group’s higher probable upside, analysts plainly believe Interpace Diagnostics Group is more favorable than Ituran Location and Control.
This table compares Ituran Location and Control and Interpace Diagnostics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ituran Location and Control||18.67%||36.12%||22.00%|
|Interpace Diagnostics Group||-37.08%||-32.06%||-11.22%|
Earnings & Valuation
This table compares Ituran Location and Control and Interpace Diagnostics Group’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Ituran Location and Control||$199.57 million||3.69||$32.13 million||$1.95||18.03|
|Interpace Diagnostics Group||$13.09 million||2.17||-$8.33 million||($0.96)||-1.33|
Ituran Location and Control has higher revenue and earnings than Interpace Diagnostics Group. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Ituran Location and Control, indicating that it is currently the more affordable of the two stocks.
Ituran Location and Control pays an annual dividend of $0.96 per share and has a dividend yield of 2.7%. Interpace Diagnostics Group does not pay a dividend. Ituran Location and Control pays out 49.2% of its earnings in the form of a dividend.
Risk and Volatility
Ituran Location and Control has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
Insider & Institutional Ownership
51.6% of Ituran Location and Control shares are held by institutional investors. Comparatively, 7.2% of Interpace Diagnostics Group shares are held by institutional investors. 0.7% of Interpace Diagnostics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Ituran Location and Control beats Interpace Diagnostics Group on 9 of the 13 factors compared between the two stocks.
About Ituran Location and Control
Ituran Location and Control Ltd. is a provider of location-based services, consisting of stolen vehicle recovery (SVR), fleet management services and other tracking services. The Company also provides wireless communication products used in connection with its location-based services and various other applications. Its operations consist of two segments: location-based services and wireless communications products. Its location-based services segment consists of its SVR and tracking services, fleet management and value-added services consisted of personal locater services and concierge services. Its wireless communications products segment consists of short and medium range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location (AVL) and automatic vehicle identification. It primarily provides its services, as well as sells and leases its products in Israel, Brazil, Argentina and the United States.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
Receive News & Ratings for Ituran Location and Control Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ituran Location and Control Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.